For future studies, a screening of reproductive health from patients with triple-negative breast cancer enrolled in clinical trials (ClinicalTrials.gov identifier: NCT02203513) using the CHK1/2 inhibitor (LY2606368) is necessary to clarify the gonadotoxicity of CHK2 inhibitor in humans. Here, CHEK2 is linked to triple-negative breast carcinoma.